Aditya Dilip Joshi

Aditya Dilip Joshi

Auto-generated profile, based on publicly available information

Aditya Dilip Joshi

Department of Pharmaceutical Sciences, University of Oklahoma Health Science Center, 1110 N. Stonewall Avenue, Oklahoma City, OK 73117, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 April 2025 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
NPNikhil Y. Patil
Nikhil Y. Patil
IRIulia Rus
Iulia Rus
FAFelix Ampadu
Felix Ampadu
HSHassan M. Abu Shukair
Hassan M. Abu Shukair
SBSarah Bonvicino
Sarah Bonvicino
AJAditya D. Joshi
Aditya D. Joshi
The study showed that the absence of AhR in hepatocytes results in exacerbated metabolic dysfunction-associated steatohepatitis (MASH) in mice subjected to a Western-style high-fat, high-fructose, high-cholesterol diet. Moreover, treatment with a tryptophan catabolite, cinnabarinic acid (CA), mitigated hallmarks of MASH in an AhR-dependent manner. In conclusion, the study delineates the significance of hepatic AhR-dependent AMPK signaling in CA-mediated protection against MASH.

19 June 2026 in Science Advances
Verified
Journal Article
Open access
WJWoncheol Jung
Woncheol Jung
HAHassan Mohammed Abushukair
Hassan Mohammed Abushukair
NPNIKHIL PATIL
NIKHIL PATIL
FAFelix Ampadu
Felix Ampadu
MFMaryam Firouzi
Maryam Firouzi
TOTae Gyu Oh
Tae Gyu Oh
Microplastics (MPs) are increasingly recognized as an urgent global health concern, with mounting evidence linking their bioaccumulation to chronic disease risks. The liver, as a central organ for metabolic homeostasis and detoxification, is particularly sensitive to sustained MP exposure. However, the mechanisms underlying hepatic responses to polyethylene (PE), the most prevalent yet relatively understudied plastic type, remain poorly defined. By performing combined bulk and spatial transcriptomic analyses, we observed that PE resulted in hepatic dysfunction in mice fed on standard or metabolic dysfunction-associated steatohepatitis (MASH)–inducing diets, driving both globally and spatially distinct transcriptional alterations, including a nuclear receptor (NR), Ppara . Spatial transcriptomics uncovered the cell type heterogeneity and gene expression patterns masked in bulk analyses. Spatial clustering uncovered inflammatory hotspots characterized by reduced cellular diversity and distinct PE-responsive gene signatures. Among these, NR signaling emerged as a key regulatory axis, with Ppara identified as a modulator. We further demonstrated that Ppara regulates Anxa2 , a gene involved in damage response and tissue recovery, through enhancer and promoter binding. These findings offer insights into how PE disrupts hepatic homeostasis and underscores the value of spatial transcriptomics in elucidating environmental impacts on tissue organization and gene expression regulation. This study provides a molecular framework for understanding MP-associated disruption of liver pathophysiology and highlights potential targets for therapeutic intervention.

20 May 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
NPNIKHIL PATIL
NIKHIL PATIL
Rosario MareRosario Mare
Rosario Mare
IRIulia Rus
Iulia Rus
Francesca SciontiFrancesca Scionti
Francesca Scionti
JPJohn Powell
John Powell
VAVibhudutta Awasthi
Vibhudutta Awasthi
Metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent liver condition associated with obesity and type 2 diabetes mellitus, can progress to severe metabolic dysfunction-associated steatohepatitis (MASH). Notwithstanding recent advances in pharmacotherapy of MASH with fibrosis, treatments for early-stage disease remain limited. This study investigates the therapeutic potential of an ethanolic extract of Costus igneus, the "insulin plant powder" (IPP), in MASLD. Phytochemically, the IPP extract was rich in flavonoids (rutin, naringin, and apigenin) known for antioxidative and anti-inflammatory properties. In cultured HepG2 cells, IPP significantly attenuates lipid accumulation induced by oleic acid and modulates intracellular calcium dysregulation caused by palmitic acid. In a 12-week study on C57BL/6 J mice fed a high-fat/high-fructose/high-cholesterol diet (HF-HFC), IPP mitigated body mass gain, adiposity, fasting glucose levels, and steatosis. Furthermore, IPP reduced liver triglycerides and serum alanine aminotransferase, indicating improved liver function. IPP downregulated lipid metabolism and inflammation markers, including Srebp-1c and Tgf-β. Focused Nanostring analysis revealed complement factor D as the principal upregulated gene in mice on HF-HFC (25x vs. control). IPP treatment reduced its level to half while also increasing Cd9 transcripts. Hepatic CFD and CD9 protein levels were significantly increased after IPP treatment. These findings show the potential of IPP as a supplemental therapeutic option modulating the immune-metabolic axis and underscoring the value of polypharmacology in the management of MASLD. The beneficial effects of IPP are likely due to the synergistic anti-inflammatory actions of its bioactive compounds and warrant further investigation in a clinical setting.

5 May 2026 in JHEP Reports
Verified
Journal Article
Open access
FAFelix Ampadu
Felix Ampadu
NPNIKHIL PATIL
NIKHIL PATIL
VEVenkateswararao Eeda
Venkateswararao Eeda
IRIulia Rus
Iulia Rus
WJWoncheol Jung
Woncheol Jung
AJAditya D. Joshi
Aditya D. Joshi
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive condition and a leading driver of global liver-related morbidity. Its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), is characterized by hepatic steatosis, inflammation, hepatocellular ballooning, and fibrosis. This study aimed to define the significance of MAP4K4 (mitogen-activated protein kinase kinase kinase kinase 4) as a therapeutic target and to evaluate a novel small-molecule inhibitor, glucosyl pyrrolo-pyrimidinone (GPPD), for the mitigation of MASH. MAP4K4 expression was immunohistochemically quantified in liver biopsies from healthy individuals (n=5) and MASLD patients (n=20). The in vitro efficacy of GPPD and genetic MAP4K4-silencing (siRNA) was assessed in human primary hepatocytes, mouse hepatic organoids, HepG2, and AML12 cells challenged with oleic acid. For in vivo validation, mice were fed a high-fat/high-fructose/high-cholesterol diet and treated with GPPD for 30-weeks (n=8/group). Livers were analyzed using single-nuclei RNA sequencing to identify the molecular mechanisms of GPPD-mediated hepatoprotection. Data was analyzed using ANOVA models and expressed as mean ± standard deviation (SD) with differences considered significant at p < 0.05. Hepatic MAP4K4 expression was significantly elevated in MASLD patients compared to healthy controls, correlating with disease severity. In multiple in vitro models, both genetic silencing and GPPD treatment significantly attenuated steatosis. In vivo, prophylactic GPPD administration reduced body mass gain and adiposity while protecting against hepatic steatosis, inflammation, injury, and fibrosis. Mechanistically, while GPPD directly inhibited MAP4K4 activity, its hepatoprotective effects were associated with suppression of CaMK2 (calcium/calmodulin-dependent protein kinase II). Our results demonstrate that glucosyl pyrrolo-pyrimidinone treatment mitigates steatohepatitis with fibrosis by regulating MAP4K4-CaMK2 axis. Further investigation of GPPD will advance its development as an effective future therapeutic strategy against MASH. This study identifies the MAP4K4-CaMK2 signaling axis as a critical pathway in the pathogenesis of MASH. By demonstrating that GPPD-mediated inhibition of this pathway attenuates key hallmarks of MASH - including steatosis, inflammation, and fibrosis - our findings provide a mechanistic framework for future therapeutic intervention. Moreover, targeting MAP4K4 may address significant unmet needs of patients who are ineligible for currently approved treatments. Collectively, this research establishes a translational foundation for the development of next-generation small molecules designed at restoring metabolic homeostasis across the disease continuum.

30 June 2026 in Toxicological Sciences
Verified
Journal Article
Open access
IJIsrat Jahan
Israt Jahan
YMYadeliz A Serrano Matos
Yadeliz A Serrano Matos
AJArul Jayaraman
Arul Jayaraman
AJAditya D Joshi
Aditya D Joshi
Aryl hydrocarbon receptor nuclear translocator 2 is a member of the basic helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) family of transcription factors involved in responding to various environmental, metabolic, and chemical signals. Initially known for its involvement in neurodevelopment, ARNT2 is now recognized as an essential binding partner for other transcription factors, including single-minded homologs 1 and 2 (SIM1, SIM2), neuronal PAS domain protein 4 (NPAS4), hypoxia-inducible factor 1 (HIF1), and plausibly Aryl hydrocarbon Receptor (AHR) to regulate stress adaptation, synaptic plasticity, immune signaling, and energy balance pathways. The role of ARNT2 has also been implicated in a plethora of pathologies, including inflammation, cardiovascular diseases, neurological disorders, metabolic diseases, and cancers. This review summarizes the current knowledge of ARNT2’s structure, regulation, interacting partners, and its toxicopathological significance. A better understanding of ARNT2 biology may open new avenues for its characterization as a molecular target and designing novel therapeutic strategies across multiple diseases.